|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.95 EUR | +2.09% |
|
-6.98% | +11.69% |
| 03-31 | Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026 | CI |
| 03-31 | Drugmaker Dermapharm targets revenue growth - Shares retreat | DP |
Business description: Dermapharm Holding SE
Number of employees: 3,610
Sales by Activity: Dermapharm Holding SE
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Other Healthcare Products | - | - | 402M | 387M | - |
Herbal Extracts | 72.04M | 98.09M | - | - | - |
Parallel Import Business | 231M | 253M | 235M | 249M | - |
Reconciliation/Group Holding Company | -1.48M | -2.84M | -39.91M | -43.41M | - |
Branded Pharmaceuticals | - | - | 537M | 588M | - |
Branded Pharmaceuticals and Other Healthcare Products | 642M | 676M | - | - | - |
Geographical breakdown of sales: Dermapharm Holding SE
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
France | - | - | 152M | 139M | - |
Others | - | - | 89.75M | 104M | - |
Spain | 75.29M | 78.02M | 118M | 118M | - |
Eastern Europe | 38.78M | 49.96M | - | - | - |
Austria/Switzerland | 42.19M | 43.21M | 68.57M | 94.86M | - |
Germany | 787M | 854M | 707M | 726M | - |
Executive Committee: Dermapharm Holding SE
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/07/2017 | |
| Director of Finance/CFO | - | 31/10/2022 | |
Britta Hamberger
IRC | Investor Relations Contact | - | 30/11/2018 |
Andreas Eberhorn
SAM | Sales & Marketing | 51 | 31/08/2022 |
Composition of the Board of Directors: Dermapharm Holding SE
| Director | Title | Age | Since |
|---|---|---|---|
Wilhelm Beier
CHM | Chairman | 70 | 31/07/2017 |
Erwin Kern
BRD | Director/Board Member | 65 | 31/07/2017 |
| Director/Board Member | 77 | 31/12/2017 |
Company details: Dermapharm Holding SE
Group companies: Dermapharm Holding SE
| Name | Category and Sector |
|---|---|
Strathmann GmbH & Co. KG
 Strathmann GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products |
Pharmaceuticals: Major
|
Allergopharma AG
 Allergopharma AG Pharmaceuticals: MajorHealth Technology Manufactures and distributes hypoallergenic immunotherapy products |
Pharmaceuticals: Major
|
Dermapharm AG
 Dermapharm AG Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products |
Pharmaceuticals: Major
|
Dermapharm AG (Switzerland) | |
mibe GmbH
 mibe GmbH Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.09% | -6.98% | +20.25% | +8.46% | 2.78B | |
| -1.65% | +0.42% | +28.27% | +158.07% | 841B | |
| -1.18% | -1.88% | +57.16% | +45.16% | 574B | |
| -2.10% | -0.43% | +18.79% | +28.85% | 368B | |
| -0.09% | 0.00% | +30.43% | +16.21% | 320B | |
| -0.30% | -0.56% | +52.18% | +30.95% | 318B | |
| -1.03% | +0.46% | +53.35% | +7.94% | 300B | |
| -0.34% | -1.17% | +41.43% | +40.20% | 295B | |
| -1.29% | +0.89% | +22.74% | +39.61% | 189B | |
| -2.18% | -0.52% | +34.12% | +68.39% | 173B | |
| Average | -0.81% | -0.45% | +35.87% | +44.38% | 338.06B | |
| Weighted average by Cap. | -1.18% | -0.00% | +37.96% | +64.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DMP Stock
- Company Dermapharm Holding SE
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition